Last reviewed · How we verify

Inventprise Inc. — Portfolio Competitive Intelligence Brief

Inventprise Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 4 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
PCV 20 PCV 20 phase 3 Pneumococcal conjugate vaccine Streptococcus pneumoniae polysaccharide antigens (20 serotypes) Immunology / Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Epicentre · 1 shared drug class
  2. GlaxoSmithKline · 1 shared drug class
  3. Korea University Guro Hospital · 1 shared drug class
  4. Merck Sharp & Dohme LLC · 1 shared drug class
  5. Papua New Guinea Institute of Medical Research · 1 shared drug class
  6. Pfizer Inc. · 1 shared drug class
  7. Sanofi · 1 shared drug class
  8. Sanofi Pasteur, a Sanofi Company · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Inventprise Inc.:

Cite this brief

Drug Landscape (2026). Inventprise Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/inventprise-inc. Accessed 2026-05-14.

Related